TRPC5 and the path towards analgesic drug development

Franziska Denk*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

2 Citations (Scopus)
27 Downloads (Pure)


A recent study by Sadler et al. highlights transient receptor potential canonical 5 (TRPC5) as a potential target for treating pain conditions. This article discusses their findings in the context of analgesic drug development, an urgent pursuit required to combat the opioid crisis and help millions of people with chronic pain.

Original languageEnglish
Pages (from-to)687-688
Number of pages2
JournalTrends in Neurosciences
Issue number9
Publication statusPublished - Sept 2021


  • chronic pain
  • lysophosphatidylcholine
  • reproducibility
  • Trp channels


Dive into the research topics of 'TRPC5 and the path towards analgesic drug development'. Together they form a unique fingerprint.

Cite this